FDA expands Susvimo’s indications to include diabetic retinopathy

Published on May 22, 2025
Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with just one refill every 9 months
Continue reading on website
Other news

Hypoglycemia may promote a breakdown of the blood-retinal barrier, study finds

May 22, 2025
New research reveals how low blood sugar can damage the retina in diabetes, highlighting potential treatments targeting specific proteins to prevent vision loss.

Black Patients Referred Less Often for Eyecare at Diabetes Diagnosis

May 23, 2025
The critical gaps in the timely detection and management of DR among Black and Hispanic populations found in this study may contribute to the disproportionate impact of vision-threatening complications in these groups. Photo: Getty Images. Click image to enlarge. While previous research has shown that racial disparities exist regarding the prevalence of and associated vision